A meta-analysis of 15 randomized controlled trials involving 4,824 patients with high blood pressure found that sacubitril/valsartan significantly improved multiple ambulatory blood pressure measures compared with angiotensin receptor blockers (ARBs) or calcium channel blockers (CCBs), with a favorable safety profile. Compared with ARBs or CCBs, sacubitril/valsartan reduced 24-hour systolic and […]
In patients with severe asymptomatic carotid artery stenosis, carotid revascularization—either carotid artery stenting (CAS) or carotid endarterectomy (CEA)—added to intensive medical management (IMM) did not significantly improve cognitive function compared with IMM alone over up to 4 years. The CREST-2 randomized clinical trials included 2,366 US patients, of whom 2,165 […]
In patients with intermediate-high–risk acute pulmonary embolism, catheter-directed thrombolysis with alteplase plus anticoagulation significantly reduced the 7-day risk of death, recurrent pulmonary embolism, or cardiorespiratory decompensation or collapse compared with anticoagulation alone, without a significant increase in clinically relevant or major bleeding. In this Czech multicenter, open-label, randomized trial, 558 […]
In a large randomized trial, atorvastatin 40 mg daily significantly reduced major cardiovascular events by 30% among community-dwelling adults aged 70 years or older without prior cardiovascular disease, diabetes, or dementia, but it did not significantly prolong disability-free survival over a median follow-up of 5.9 years. The double-blind, placebo-controlled trial […]
In patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), aficamten significantly improved exercise capacity and patient-reported health status compared with placebo at 36 weeks. In this phase 3 multinational, double-blind trial, 517 adults were randomly assigned to receive aficamten or placebo for up to 72 weeks. At week 36, the Kansas […]
In patients with atrial fibrillation at intermediate risk for stroke, direct oral anticoagulant (DOAC) therapy significantly reduced the 24-month risk of a composite of stroke, systemic embolism, major bleeding, or cardiovascular death compared with no anticoagulation. In the Korean multicenter, open-label, adjudicator-masked randomized trial, 1,803 patients with a CHA₂DS₂-VASc score […]
A randomized clinical trial found that a single 25 mg dose of psilocybin produced rapid antidepressant effects in patients with moderate to severe recurrent major depressive disorder (MDD), with benefits emerging by day 2 and persisting for more than 3 months on several secondary measures. Conducted at the Northern Stockholm […]
Intensive blood pressure (BP) control targeting <130/80 mm Hg reduced cardiovascular events and mortality consistently across all baseline diastolic blood pressure (DBP) strata in a post hoc analysis of 33,288 participants from the China Rural Hypertension Control Project, with no evidence that lower DBP diminished benefit. Participants were categorized into […]
In patients with ST-segment elevation myocardial infarction (STEMI), early subcutaneous administration of zalunfiban significantly improved coronary artery patency and reduced the risk of adverse 30-day clinical outcomes without increasing severe bleeding. In an international, double-blind, placebo-controlled trial of 2,467 patients randomly assigned to receive zalunfiban (0.11 mg/kg or 0.13 mg/kg) […]
A systematic review and network meta-analysis evaluated the efficacy and safety of different exercise modalities for managing knee osteoarthritis, including aerobic, flexibility, mind-body, neuromotor, strengthening, and mixed exercises. A total of 217 randomized controlled trials involving 15,684 participants were analyzed, with outcomes assessed at short-term (4 weeks), mid-term (12 weeks), […]